Meeting
2018 Genitourinary Cancers Symposium
A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
Authors
Karim Chamie
University of California Los Angeles, Los Angeles, CA
Karim Chamie , Amirali Salmasi , Charles Joel Rosser , Amy Rock , Lydia Ferguson , Hing C. Wong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral and Testicular Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Clinical Trial Registration Number
NCT03022825
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr TPS544)
DOI
10.1200/JCO.2018.36.6_suppl.TPS544
Abstract #
TPS544
Poster Bd #
N22
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
An in-progress phase 2 window of opportunity (WOO) trial of targeted therapy with erdafitinib for patients with recurrent FGFR3-altered non–muscle-invasive bladder cancer (NMIBC).
First Author: Neeta DSouza
Poster
2023 ASCO Genitourinary Cancers Symposium
The impact of blue light cystoscopy use among patients with non-muscle invasive bladder cancer in an equal access setting.
First Author: Sanjay Das
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel
Poster
2023 ASCO Genitourinary Cancers Symposium
Response Evaluation Criteria in Tumors of the Bladder (RECIT-Bladder) for future window of opportunity trials as a platform to accelerate drug development.
First Author: Christopher Gaffney